Securities Code: 301520
Securities Abbreviation: Wanbang Pharmaceutical
Announcement Number: 2026-024
Anhui Wanbang Pharmaceutical Technology Co., Ltd.
Announcement on Abnormal and Severe Abnormal Fluctuations in Stock Trading
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
Special Reminders:
-
The stock trading price of Anhui Wanbang Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") (Securities Abbreviation: Wanbang Pharmaceutical, Securities Code: 301520) has experienced abnormal fluctuations and severe abnormal fluctuations. The cumulative increase in closing price deviation over three consecutive trading days (July 9, 2026, July 10, 2026, and July 13, 2026) exceeded 30%, and the cumulative increase in closing price deviation over ten consecutive trading days (June 30, 2026, to July 13, 2026) exceeded 100%. In accordance with the "Trading Rules of Shenzhen Stock Exchange" and other relevant regulations, this constitutes abnormal and severe abnormal fluctuations in stock trading.
-
As of July 10, 2026, according to the latest data from Wind Information Co., Ltd., the Company's trailing P/E ratio was 173.06 times. The trailing P/E ratio for the "M73 Research and Experimental Development" industry classification of the China Association of Industry Associations, to which the Company belongs, was 27.30 times. The Company's latest P/E ratio is significantly higher than the average level of comparable listed companies in the same industry. Investors are kindly requested to pay attention to investment risks.
-
The Company plans to disclose its "2026 Semi-Annual Report" on August 29, 2026. The specific financial data will be subject to the relevant reports disclosed by the Company. As of the disclosure date of this announcement, the preparation of the Company's 2026 Semi-Annual Report is underway and no financial data for the first half of 2026 has been provided to any third party.
-
Due to the severe abnormal fluctuations in the Company's stock trading and the overheated market sentiment and irrational speculation, there may be irrational trading behaviors, and the trading risk is high, with the risk of significant price increases followed by sharp declines. The Company solemnly reminds investors to pay attention to the risks of secondary market trading, make rational judgments, and invest prudently.